Clinical trials
Total Neoadjuvant Therapy clinical trials
Below are recruiting total neoadjuvant therapy clinical trials, each written for real people, not researchers. We’re tracking 172 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05861505RecruitingPhase 3
Treatment for new liver spread from colon cancer recurrence
This Phase 3 trial studies a treatment approach for people whose colorectal cancer has come back in the liver within 12 months and can be treated with local procedures. It aims to see whether the study treatment can improve outcomes compared with standard care for people with a limited number of liver tumors.
AmsterdamAges 18 years+ - NCT05301283RecruitingPhase 2
Adaptive radiation therapy before surgery for soft-tissue sarcoma
This trial tests a personalized (“adaptive”) radiation plan before surgery for high-grade soft-tissue sarcoma that can be removed. It may help shrink the tumor and improve how well surgery can treat the cancer.
Tampa, FloridaAges 18 years+ - NCT06056336RecruitingPhase 2
Perioperative tislelizumab plus chemo for esophageal cancer
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07854600RecruitingPhase 2
Ivonescimab plus chemotherapy before surgery for bile duct cancer
This trial tests a new drug combination given before surgery to shrink bile duct cancer tumors, potentially making surgery more successful. It is for patients whose cancer is locally advanced or has spread to only a few places.
Beijing, Beijing MunicipalityAges 18–80 - NCT07387198RecruitingPhase 2
Testing cemiplimab before surgery for Merkel cell carcinoma
This trial tests whether giving the immunotherapy drug cemiplimab before surgery can improve outcomes for people with stage I or II Merkel cell carcinoma. If you qualify, you would receive cemiplimab before your sentinel lymph node biopsy.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06970912RecruitingPhase 2
ctDNA-Guided Reduced Chemo in HR+/HER2- Breast Cancer
This study is testing whether using a ctDNA blood test can help doctors decide if patients with hormone receptor-positive, HER2-negative breast cancer can safely receive less intensive chemotherapy after surgery. The goal is to reduce side effects while still preventing the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT06714084Enrolling by invitation
Treating high-risk cervical cancer with chemoradiation and immunotherapy
This trial tests a new drug called Cardenimumab combined with standard chemotherapy and radiation for women with high-risk cervical cancer. The goal is to see if adding this drug can improve outcomes for patients whose tumors are large, have spread to lymph nodes, or are stage IV.
Wuhan, HubeiAges 18–75 - NCT07340398RecruitingPhase 2
Testing new drug combos for HER2-positive breast cancer not responding to first therapy
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
HangzhouAges 18–75 - NCT07213934RecruitingPhase 1/Phase 2
Immunotherapy and radiation before surgery for recurrent head and neck cancer
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
Cincinnati, OhioAges 18 years+ - NCT07796880RecruitingPhase 2
Study of a new drug with hormone therapy before breast cancer surgery
This trial tests a new drug called culmerciclib when given with hormone therapy before breast cancer surgery. The goal is to see if this combination can shrink tumors and improve outcomes for patients with hormone-receptor-positive, HER2-negative breast cancer.
Guangzhou, GuangdongAges 18–70 - NCT07528716RecruitingPhase 3
AI-guided treatment for HER2-positive breast cancer
This trial tests whether an artificial intelligence model can help doctors choose the best targeted therapy before surgery for HER2-positive breast cancer (a type of breast cancer with a protein called HER2). The goal is to improve how well the treatment works and reduce side effects.
ShanghaiAges 18–75 - NCT03821246RecruitingPhase 2
Atezolizumab and other drugs before prostate surgery for high-risk cancer
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
San Francisco, CaliforniaAges 18 years+ - NCT07337811Recruiting
Selective removal of rectal cancer after radiation and chemotherapy
This trial tests how well a precise surgery removes the remaining rectal cancer after you have had radiation and chemotherapy. It is for people whose tumor has shrunk a lot but is still there, and the tumor is very low in the rectum.
Guangzhou, GuanggongAges 18–75 - NCT06025747RecruitingPhase 1
Abemaciclib plus radiation for liposarcoma before surgery
This trial tests a combination of the targeted drug abemaciclib and radiation therapy before surgery for people with a specific type of liposarcoma. The goal is to see if this combination can shrink the tumor and help make surgery more effective.
Seattle, WashingtonAges 18 years+ - NCT04741997RecruitingEarly Phase 1
Adjuvant melanoma treatment guided by response to targeted drugs
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
Tampa, FloridaAges 18 years+ - NCT07016399RecruitingPhase 2
Darolutamide before surgery for AR-positive triple-negative breast cancer
This trial tests a drug called darolutamide, alone or with standard chemotherapy, before surgery for a type of breast cancer that is triple-negative but has a high level of the androgen receptor (AR). It is for people with stage II or IIIA breast cancer that can be removed surgically.
Nashville, TennesseeAges 18 years+ - NCT05148767RecruitingPhase 4
UGT1A1-guided irinotecan for locally advanced rectal cancer
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
Hangzhou, ZhejiangAges 18–75 - NCT06208826RecruitingPhase 2
Immunotherapy maintenance after surgery for head and neck cancer
This trial looks at whether continuing immunotherapy can help keep cancer from coming back in people with head and neck cancer who had a good response to chemo-immunotherapy before surgery. You would have already had surgery, and now the study tests a maintenance treatment to strengthen your immune system's fight against any remaining cancer cells.
Tianjin, Tianjin MunicipalityAges 18–80 - NCT06288373RecruitingPhase 2/Phase 3
Comparing chemoimmunotherapy vs chemoradiation for advanced cervical cancer before surgery
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
Hefei, AnhuiAges 18–70 - NCT07049848RecruitingPhase 2
Study of atezolizumab with chemo and radiation for high-risk sarcoma
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
Houston, TexasAges 18 years+ - NCT05980715RecruitingPhase 3
Comparing immunotherapy to radiation after successful treatment for head and neck cancer
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
Guangzhou, GuangdongAges 18–65 - NCT04821843RecruitingPhase 3
Study before-surgery treatments for esophageal cancer
This Phase 3 trial compares different “treatments before surgery” for people with esophageal (or esophagus-to-stomach) cancer. It aims to see which approach works better to control the cancer and improve outcomes after surgery.
BeijingAges 18 years+ - NCT07748325RecruitingPhase 2
Checking if immunotherapy after surgery helps prevent lung cancer return
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
Chengdu, SichuanAges 18–75 - NCT06831526RecruitingEarly Phase 1
Chemoradiation with or without azeliragon for new glioblastoma
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
St Louis, MissouriAges 18 years+
Hear when a new Total Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for total neoadjuvant therapy?
- Yes. Clin2 currently lists 172 recruiting total neoadjuvant therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a total neoadjuvant therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a total neoadjuvant therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.